| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $1,204,518 | 3 | 100 |
| Echelard Yann | director | 0 | $0 | 2 | $532,250 | $-532,250 |
| Lonial Sagar | director | 0 | $0 | 1 | $672,268 | $-672,268 |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Over the last 12 months, insiders at TG Therapeutics, Inc. have bought $0 and sold $1.2M worth of TG Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at TG Therapeutics, Inc. have bought $554,380 and sold $2.25M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 100,000 shares for transaction amount of $1.01M was made by WEISS MICHAEL S (CEO and President) on 2023‑08‑11.
| 2025-11-24 | Sale | Echelard Yann | director | 5,000 0.0032% | $32.57 | $162,850 | -5.14% | |
| 2025-09-11 | Sale | Lonial Sagar | director | 20,852 0.0131% | $32.24 | $672,268 | -4.37% | |
| 2025-06-13 | Sale | Echelard Yann | director | 10,000 0.0065% | $36.94 | $369,400 | -12.33% | |
| 2025-01-06 | Sale | Power Sean A | CFO | 10,021 0.0065% | $28.53 | $285,939 | +21.75% | |
| 2025-01-03 | Sale | Power Sean A | CFO | 11,337 0.0073% | $30.29 | $343,443 | +13.61% | |
| 2024-11-11 | Sale | Charney Laurence N | director | 25,000 0.0157% | $30.20 | $754,875 | +12.39% | |
| 2024-11-11 | Sale | Lonial Sagar | director | 5,000 0.0032% | $30.44 | $152,200 | +12.39% | |
| 2024-11-05 | Sale | Echelard Yann | director | 20,000 0.0131% | $24.48 | $489,600 | +33.60% | |
| 2024-06-20 | Sale | Lonial Sagar | director | 16,348 0.011% | $16.87 | $275,791 | +81.36% | |
| 2024-06-17 | Sale | Lonial Sagar | director | 9,585 0.0063% | $16.39 | $157,098 | +85.40% | |
| 2024-03-13 | Sale | Lonial Sagar | director | 5,000 0.0033% | $15.94 | $79,675 | +47.23% | |
| 2024-03-12 | Sale | Charney Laurence N | director | 22,000 0.0144% | $15.97 | $351,340 | +45.96% | |
| 2024-01-05 | Sale | Charney Laurence N | director | 17,500 0.0112% | $19.03 | $333,025 | -2.29% | |
| 2024-01-03 | Sale | Power Sean A | CFO | 47,867 0.0318% | $16.91 | $809,431 | +13.54% | |
| 2023-08-11 | WEISS MICHAEL S | CEO and President | 100,000 0.0669% | $10.13 | $1.01M | +51.09% | ||
| 2023-06-23 | Sale | Lonial Sagar | director | 34,854 0.0246% | $23.37 | $814,538 | -36.08% | |
| 2023-06-02 | Sale | Power Sean A | Chief Financial Officer | 73,647 0.0528% | $26.70 | $1.97M | -43.20% | |
| 2023-01-06 | Echelard Yann | director | 9,000 0.0063% | $10.64 | $95,760 | +45.42% | ||
| 2023-01-04 | Sale | Charney Laurence N | director | 30,000 0.0221% | $11.10 | $333,000 | +44.40% | |
| 2022-01-05 | Sale | WEISS MICHAEL S | CEO and President | 30,671 0.0239% | $18.31 | $561,586 | -57.97% |
| Echelard Yann | director | 223816 0.141% | $6.5M | 1 | 4 | +45.42% |
| Lonial Sagar | director | 94061 0.0592% | $2.73M | 0 | 6 | |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 12629868 7.9553% | $366.65M | 0 | 1 | |
| WEISS MICHAEL S | CEO and President | 12073021 7.6046% | $350.48M | 6 | 3 | +67.94% |
| LFB Biotechnologies S.A.S.U. | 10 percent owner | 5114855 3.2218% | $148.48M | 1 | 0 | +3.39% |
| GIMBERT JOAN PONS | 3957037 2.4925% | $114.87M | 0 | 1 | ||
| ROSENWALD LINDSAY A MD | 10 percent owner | 2649321 1.6688% | $76.91M | 59 | 0 | |
| WEISER MICHAEL | director | 2213338 1.3941% | $64.25M | 1 | 0 | |
| Power Sean A | CFO | 660611 0.4161% | $19.18M | 2 | 23 | |
| Charney Laurence N | director | 212479 0.1338% | $6.17M | 0 | 5 | |
| KENNEDY WILLIAM JAMES | director | 94633 0.0596% | $2.75M | 0 | 4 | |
| Herskowitz Neil | director | 51265 0.0323% | $1.49M | 8 | 0 | +168.29% |
| ABEL DOUGLAS | President and CEO | 30000 0.0189% | $870,900.00 | 8 | 0 |
$66,736,176 | 136 | 27.54% | $4.06B | |
$193,151,375 | 134 | 8.18% | $4.5B | |
$52,263,649 | 70 | 1.18% | $3.74B | |
$224,382,625 | 44 | 27.62% | $4.41B | |
$477,065,869 | 34 | 82.05% | $5.44B | |
$1,275,975,557 | 32 | 19.44% | $3.79B | |
$61,717,660 | 28 | 36.84% | $3.78B | |
$27,105,902 | 21 | -16.06% | $4.81B | |
$74,605,681 | 14 | 47.06% | $5.5B | |
$57,686,748 | 13 | 21.11% | $5.24B | |
$91,269,919 | 12 | 12.86% | $3.99B | |
$2,477,801 | 11 | 4.98% | $4.72B | |
$35,908,794 | 10 | 126.31% | $5.83B | |
$3,073,199 | 10 | 16.77% | $5.33B | |
$1,711,150 | 9 | 31.59% | $3.64B | |
$25,064,843 | 9 | 12.75% | $4.71B | |
TG Therapeutics, Inc. (TGTX) | $2,246,813 | 6 | 70.15% | $4.61B |
$50,990,767 | 2 | 19.79% | $3.89B | |
$7,600,000 | 1 | -4.05% | $4.99B |
| Increased Positions | 196 | +49.75% | 12M | +12.01% |
| Decreased Positions | 171 | -43.4% | 8M | -7.64% |
| New Positions | 64 | New | 3M | New |
| Sold Out Positions | 54 | Sold Out | 2M | Sold Out |
| Total Postitions | 419 | +6.35% | 104M | +4.37% |
| Blackrock, Inc. | $623,676.00 | 13.4% | 21.3M | -512,881 | -2.35% | 2025-09-30 |
| Vanguard Group Inc | $454,464.00 | 9.76% | 15.52M | -288,018 | -1.82% | 2025-09-30 |
| State Street Corp | $237,186.00 | 5.1% | 8.1M | +482,381 | +6.33% | 2025-09-30 |
| Clearbridge Investments, Llc | $135,990.00 | 2.92% | 4.64M | +2M | +52.15% | 2025-09-30 |
| Soleus Capital Management, L.P. | $112,574.00 | 2.42% | 3.84M | +2M | +71.34% | 2025-09-30 |
| Geode Capital Management, Llc | $100,838.00 | 2.17% | 3.44M | -46,538 | -1.33% | 2025-09-30 |
| Pictet Asset Management Holding Sa | $47,128.00 | 1.01% | 1.61M | -297,940 | -15.62% | 2025-09-30 |
| Hood River Capital Management Llc | $45,466.00 | 0.98% | 1.55M | -14,718 | -0.94% | 2025-09-30 |
| Goldman Sachs Group Inc | $44,487.00 | 0.96% | 1.52M | -50,536 | -3.22% | 2025-09-30 |
| Northern Trust Corp | $43,971.00 | 0.94% | 1.5M | -33,990 | -2.21% | 2025-09-30 |